MeAgain keeps your symptoms, cycle notes, meals, hydration, weight trend, and weekly shot in one app, so the question of what changed after starting a GLP-1 gets answered with dates instead of guesses by you and by the clinician who knows your history
The initial clinical data are encouraging, indicating that Orforglipron produces desirable hypoglycemic activity and also induces weight loss in trial subjects
As the above-mentioned group has analyzed, pharmaceutical drugs are part of the therapies but not the final solution
A patient who has already been on GLP-1 treatment through a compounding platform, is comfortable with the compounded medication model, and is looking for a continuation of that access pathway as the regulatory environment evolves
By managing some of these systems, GLP-1 might also play a role in pathways related to longevity
A role for cAMP and protein kinase A in experimental necrotizing enterocolitis